Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants aged 18 to 65 years with established SLE. Participants must have active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at screening of positive anti-nuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.~* Enrolled participants must be treated with background SLE medications.~Exclusion Criteria:~* Participants with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of malignancy, history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women.~* Participants with severe SLE disease or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cenerimod 0.5 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
- Cenerimod 1 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
- Cenerimod 2 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
- Cenerimod 4 mg (Part B) (Type: EXPERIMENTAL): Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
- Matching placebo (Part A and B) (Type: PLACEBO_COMPARATOR): Capsules of matching placebo taken orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).